- Home
- CLDI vs FRSX Comparison
CLDI vs FRSX Comparison
Compare CLDI & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- FRSX
- Stock Information
- Founded
- CLDI 2014
- FRSX N/A
- Country
- CLDI United States
- FRSX Israel
- Employees
- CLDI N/A
- FRSX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- FRSX Computer Software: Prepackaged Software
- Sector
- CLDI Health Care
- FRSX Technology
- Exchange
- CLDI Nasdaq
- FRSX Nasdaq
- Market Cap
- CLDI 10.2M
- FRSX 9.8M
- IPO Year
- CLDI N/A
- FRSX 2017
- Fundamental
- Price
- CLDI $0.23
- FRSX $0.51
- Analyst Decision
- CLDI Strong Buy
- FRSX
- Analyst Count
- CLDI 1
- FRSX 0
- Target Price
- CLDI $10.00
- FRSX N/A
- AVG Volume (30 Days)
- CLDI 1.8M
- FRSX 440.7K
- Earning Date
- CLDI 08-12-2025
- FRSX 08-08-2025
- Dividend Yield
- CLDI N/A
- FRSX N/A
- EPS Growth
- CLDI N/A
- FRSX N/A
- EPS
- CLDI N/A
- FRSX N/A
- Revenue
- CLDI N/A
- FRSX $436,000.00
- Revenue This Year
- CLDI N/A
- FRSX N/A
- Revenue Next Year
- CLDI N/A
- FRSX N/A
- P/E Ratio
- CLDI N/A
- FRSX N/A
- Revenue Growth
- CLDI N/A
- FRSX N/A
- 52 Week Low
- CLDI $0.20
- FRSX $0.45
- 52 Week High
- CLDI $3.89
- FRSX $2.63
- Technical
- Relative Strength Index (RSI)
- CLDI 21.13
- FRSX 40.79
- Support Level
- CLDI $0.31
- FRSX $0.45
- Resistance Level
- CLDI $0.33
- FRSX $0.52
- Average True Range (ATR)
- CLDI 0.04
- FRSX 0.04
- MACD
- CLDI -0.01
- FRSX -0.00
- Stochastic Oscillator
- CLDI 14.83
- FRSX 25.15
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About FRSX Foresight Autonomous Holdings Ltd.
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.